AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all previous versions, and listings, of claims in the application.

1. (Cancelled)

2. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in claim 1~~ wherein A is - O-.

3. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein B is -O-.

4. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein g is 0, 1 or 2.

5. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein R_1 represents halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, hydroxy, or two adjacent R_1 groups together with the carbon atoms to which they are attached form a fused benzene ring.

6. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein R_1 represents methoxy, fluoro, chloro, hydroxy, or two adjacent R_1 groups together with the carbon atoms to which they are attached form a fused benzene ring.

7. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein R_2 is H or an alkyl group containing 1 to 3 carbon atoms.

8. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein R_3 and R_4, which are the same or different, are H or methyl.

9. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein T is pyridyl, pyrimidinyl, pyrazinyl, phenyl, benzofuryl, 1,4- benzodioxanyl or quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

10. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein T is 2-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, phenyl, 2,3-dihydrobenzo[b]furan-7-yl, 1,4-benzodioxan-5-yl or 4-quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

11. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in any preceding claim~~ wherein R_5 is H or methyl.

12. (Currently amended) A method according to claim 21, ~~The use of compounds of formula I as claimed in claim 1 which are~~ wherein the compound of formula I includes at least one of:

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrazin-2-yl)piperid-4- yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(3-chloropyrid-2-yl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(quinazolin-4-yl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl)piperid-4-yl]methylamine;

N-(8-Methoxy-1,4-benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-N'-[3-(trifluoromethyl)-2- pyridyl]ethanediamine;

N-(8-Methoxy-1,2,3,4-tetrahydronaphth-2-ylmethyl)-1-[1-pyrimidin-2- yl)piperid-4-yl]methylamine;

7-{N-[l-(Pyrimidin-2-yl)piperid-4-ylmethyl]aminomethyl}-5,6,7,8- tetrahydronaphth-1-ol;

N-(5-Methoxy-3,4-dihydro-2H-1 -benzopyran-3-ylmethyl)-l-[1-(pyrimidin-2-yl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-(1-phenylpiperid-4-yl)methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(1,4-benzodioxan-5-yl)piperid-4-yl]methylamine;

1-[1-(1,4-Benzodioxan-2-ylmethyl)piperid-4-yl]-N-(2-methoxyphenyl)methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(4-methoxyphenyl)piperid-4-yl]methylamine;

N-(8-Methoxy-1,4-benzodioxan-2-ylmethyl)-N' -(2-methoxyphenyl)-1,3-propanediamine;

N-(1,4-Benzodioxan-2-ylmethyl)-l-[1-(3-methoxyphenyl)piperid-4-yl]methylamine;

N-(6,7-Dichloro-1,4-benzodioxan-2-ylmethyl)-1-[1-(2- methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-chlorophenyl)piperid-4-yl]methylamine;

N-(5-Fluoro-1,4-benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

N-(8-Fluoro-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2-methoxyphenyl)piperid-4-yl]methylamine;

1-[1-(2-methoxyphenyl)piperid-4-yl]-N-(naphtho[1,2-b]dioxan-2-ylmethyl)methylamine;

1-[1-(2,3-Dihydrobenzo[b]furan-7-yl)piperid-4-yl]-N-(8-methoxy-1,4- benzodioxan-2-ylmethyl)methylamine;

N-(6-Chloro-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2- methoxyphenyl)piperid-4-yl]methylamine;

N-(7-Chloro-1,4-benzodioxan-2-ylmethyl)-1-[1-(2- methoxyphenyl)piperid-4-yl]methylamine;

N-(8-hydroxy-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2-methoxyphenyl)piperid-4-yl]methylamine;

and pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

13. (Currently amended) A method according to claim 12, ~~The use of compounds of formula I as claimed in claim 12 which are~~ wherein the compound of formula I includes at least one of: [[-]]

(S)-(-)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

(R)-(+)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

(-)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl)piperid-4-yl]methylamine dihydrochloride;

(+)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl)piperid-4-yl]methylamine dihydrochloride.

14. (Currently amended) A method according to claim 21, wherein the therapeutically effective amount of a compound includes a compound of formula I ~~The use of compounds of formula I~~



I

and pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which

A is -O-;

B is -O-;

g is 0 or 1;

R_1 represents halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, or hydroxy;

R_2, R_3 and R_4 are each H;

U is methylene;

Q is a group of formula IIa or IIc



IIa



IIc

in which V is methylene or ethylene; X is an alkylene chain containing 0 to 2 carbon atoms and X' is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms in X and X' amounts to 3 or 4; and R_5 is H; and

T is pyridyl, pyrazinyl, phenyl, benzo[b]furanyl, 1,4-benzodioxanyl, or quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo; ~~for use in reducing cravings to food or an addictive substance~~ to a patient in need thereof.

15. (Currently amended) A method according to claim 14, ~~The use of compounds of formula I as claimed in claim 14~~ wherein R_1 represents methoxy, fluoro, chloro or hydroxy.

16. (Currently amended) A method according to claim 14, ~~The use of compounds of formula I as claimed in claim 14~~ wherein T is 2-pyridyl, 2-pyrazinyl, phenyl, 2,3-dihydrobenzo[b]furan-7-yl, 1,4-benzodioxan-5-yl or 4-quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

17. (Currently amended) A method according to claim 14, ~~The use of compounds of formula I as claimed in claim 14 selected from~~ wherein the compound of formula I includes at least one of:

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrazin-2-yl)piperid-4- yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(3-chloropyrid-2-yl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(quinazolin-4-yl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl)piperid-4-yl]methylamine;

N-(8-Methoxy-1,4-benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-(1-phenylpiperid-4-yl)methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(1,4-benzodioxan-5-yl)piperid-4-yl]methylamine;

1-[1-(1,4-Benzodioxan-2-ylmethyl)piperid-4-yl]-N-(2-methoxyphenyl)methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(4-methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-l-[1-(3-methoxyphenyl)piperid-4-yl]methylamine;

N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-chlorophenyl)piperid-4-yl]methylamine;

N-(5-Fluoro-1,4-benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

N-(8-Fluoro-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2-methoxyphenyl)piperid-4-yl]methylamine;

1-[1-(2,3-Dihydrobenzo[b]furan-7-yl)piperid-4-yl]-N-(8-methoxy-1,4- benzodioxan-2-ylmethyl)methylamine;

N-(6-Chloro-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2- methoxyphenyl)piperid-4-yl]methylamine;

N-(7-Chloro-1,4-benzodioxan-2-ylmethyl)-1-[1-(2- methoxyphenyl)piperid-4-yl]methylamine;

N-(8-hydroxy-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2-methoxyphenyl)piperid-4-yl]methylamine;

and pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

18. (Currently amended) A method according to claim 14, ~~The use of compounds of formula I as claimed in claim 14 which are~~ wherein the compound of formula I includes at least one of: [[-]]

(S)-(-)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

(R)-(+)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(2-methoxyphenyl)piperid-4-yl]methylamine;

(-)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl)piperid-4-yl]methylamine dihydrochloride;

(+)-N-(1,4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl)piperid-4-yl]methylamine dihydrochloride.

19. (Currently amended) ~~The~~ A compound of ~~formula I as claimed in claim 14 which is:~~

N-(7-Chloro-1,4-benzodioxan-2-ylmethyl)-1-[1 -(2-methoxyphenyl)piperid-4-yl]methylamine; and pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

20. (Currently amended) A method according to claim 14 or 21, wherein ~~The use of pharmaceutical compositions comprising a~~ the therapeutically effective amount of a compound of formula I includes ~~, together with~~ a pharmaceutically acceptable diluent or carrier ~~in reducing cravings to food or an addictive substance~~.

21. (Currently amended) A method of reducing cravings to food or an addictive substance which comprises the administration of a therapeutically effective amount of a compound of formula I



I

including pharmaceutically acceptable salts thereof in which

A is methylene or -O-;

B is methylene or -O-;

g is 0, 1, 2, 3 or 4;

R_1 represents a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group

containing 1 to 3 carbon atoms, g) hydroxymethyl, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, l) a sulphamoyl or sulphamoylmethyl group each optionally N- substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; or two adjacent R_1 groups together with the carbon atoms to which they are attached form a fused benzene ring, the substituents represented by R_1 being the same or different when g is 2, 3 or 4;

R_2 is H, an alkyl group containing 1 to 3 carbon atoms, or an alkoxy group containing 1 to 3 carbon atoms;

R_3 and R_4, which are the same or different, are H, or an alkyl group containing 1 to 3 carbon atoms;

U is an alkylene chain containing 1 to 3 carbon atoms, optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

Q represents a divalent group of formula IIa, IIb or IIc



IIa



IIb



IIc

in which V is a bond or an alkylene chain containing 1 to 3 carbon atoms optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

V' is an alkylene chain containing 2 to 6 carbon atoms, optionally substituted by one or more alkyl groups containing 1 to 3 carbon atoms;

X is an alkylene chain containing 0 to 2 carbon atoms and X' is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms in X and X' amounts to 3 or 4;

R_5 is H or an alkyl group containing 1 to 3 carbon atoms; and

T represents an aromatic group optionally containing one or more N atoms and optionally substituted by one or more substituents selected from halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, or a polyhalogenated alkyl group, or T represents benzo[b]furanyl or benzodioxanyl with the proviso that T is not 2-pyrimidinyl when A is -O-;

~~as claimed in any of claims 1 to 19~~ to a patient in need thereof.

22. (Original) A method as claimed in claim 15 wherein the addictive substance is cocaine, amphetamine, nicotine, opiates, tobacco, alcohol or ecstasy.

23. (Currently amended) A method of producing a substance to reduce ~~The use of a compound of formula I as claimed in any of claims 1 to 19 in the manufacture of a medicament for use in reducing~~ cravings to food or an addictive substance comprising:

manufacturing a medicament that includes a therapeutically effective amount of a compound of formula I



I

including pharmaceutically acceptable salts thereof in which

A is methylene or -O-;

B is methylene or -O-;

g is 0, 1, 2, 3 or 4;

R_1 represents a) halo, b) an alkyl group containing 1 to 3 carbon atoms optionally substituted by one or more halo, c) an alkoxy group containing 1 to 3 carbon atoms optionally substituted by one or more halo, d) an alkylthio group containing 1 to 3 carbon atoms optionally substituted by one or more halo, e) hydroxy, f) an acyloxy group containing 1 to 3 carbon atoms, g) hydroxymethyl, h) cyano, i) an alkanoyl group containing 1 to 6 carbon atoms, j) an alkoxycarbonyl group containing 2 to 6 carbon atoms, k) a carbamoyl group or carbamoylmethyl group each optionally N-substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, l) a sulphamoyl or sulphamoylmethyl group each optionally N- substituted by one or two alkyl groups each containing 1 to 3 carbon atoms, m) an amino group optionally substituted by one or two alkyl groups each containing 1 to 3 carbon atoms; or two adjacent R_1 groups together with the carbon atoms to which they are attached form a fused benzene ring, the substituents represented by R_1 being the same or different when g is 2, 3 or 4;

R_2 is H, an alkyl group containing 1 to 3 carbon atoms, or an alkoxy group containing 1 to 3 carbon atoms;

R_3 and R_4, which are the same or different, are H, or an alkyl group containing 1 to 3 carbon atoms;

U is an alkylene chain containing 1 to 3 carbon atoms, optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

Q represents a divalent group of formula IIa, IIb or IIc



IIa



IIb



IIc

in which V is a bond or an alkylene chain containing 1 to 3 carbon atoms optionally substituted by one or more alkyl groups each containing 1 to 3 carbon atoms;

V' is an alkylene chain containing 2 to 6 carbon atoms, optionally substituted by one or more alkyl groups containing 1 to 3 carbon atoms;

X is an alkylene chain containing 0 to 2 carbon atoms and X' is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms in X and X' amounts to 3 or 4;

R_5 is H or an alkyl group containing 1 to 3 carbon atoms; and

T represents an aromatic group optionally containing one or more N atoms and optionally substituted by one or more substituents selected from halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, or a polyhalogenated alkyl group, or T represents benzo[b]furanyl or benzodioxanyl with the proviso that T is not 2-pyrimidinyl when A is -O-.